Phase III ATLAS Trial of Carfilzomib, Lenalidomide, and Dexamethasone vs Lenalidomide Alone as Maintenance After ASCT in Patients With NDMM

Experts answer pressing audience questions from a live satellite symposium on the management of relapsed/refractory multiple myeloma, from Clinical Care Options (CCO)

Paul G. Richardson, MD
Program Director Natalie S. Callander, MD Noopur Raje, MD Released: August 18, 2022

Expert text module that provides insights from a leading patient advocate/healthcare professional on best practices in education for patients with CLL, from Clinical Care Options (CCO)

Nichole Fisher, RN, BSN Brian Koffman, MDCM (retired), MS Ed Anthony Perissinotti, PharmD, BCOP Physicians: maximum of 0.75 AMA PRA Category 1 Credits™ Registered Nurses: 0.75 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Released: August 17, 2022 Expired: August 16, 2023

Comentario experto de los datos de la EHA 2022 sobre inhibidores de la QBT para LLC y LCM de Clinical Care Options (CCO)

Othman Al-Sawaf, MD Lydia Scarfò, MD Released: August 15, 2022

Expertengespräch über die Daten der EHA 2022 zu BTK-Inhibitoren für CLL und MCL, von Clinical Care Options (CCO)

Othman Al-Sawaf, MD Lydia Scarfò, MD Released: August 15, 2022